drugset / Trial / NCT05797805
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The second part of the study will begin with a brief dose escalation part for each combination (tegavivint plus cabozantinib or tegavivint plus lenvatinib) followed by a combination dose expansion.
Timeline
- Start
- 2023-09-13
- Primary completion
- 2026-05
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Tegavivint | Small molecule | — | — |